Scott & Christie and Associates, PC
Multi-center, prospective, open-label, single-arm effectiveness of acoltremon 0.003% in improving patient signs and symptoms with dry eye disease. Subjects will be assessed at baseline, and after 7, 14, and 28 days of treatment. Clinical evaluations will include administration of the Eye Dryness Score Visual Analog Scale (EDS-VAS), measurement of visual acuity at distance, corneal fluorescein staining, conjunctival lissamine green staining, and Pain Numerical Rating Scale assessment.
Inclusion Criteria: * Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed. * Be able and willing to comply with the study requirements and attend all study visits. * Be a minimum of 18 years of age of either sex and any race or ethnicity. * Diagnosis of Dry Eye Disease at least 6 months before enrollment. * Use of or desired use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection phase. * Symptoms…
1 drop per eye, twice daily (morning and evening approximately 12 hours apart), at consistent times.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.